🚶♂️🏃♀️ Scilex is proud to participate in the 16th Annual Miles for Migraine event! 🧠🎗️ Date: Saturday, October 26, 2024 Location: Music Concourse Bandshell at Golden Gate Park | San Francisco, CA Join us at Golden Gate Park as we walk, run, and raise awareness for migraine sufferers everywhere. We’re committed to supporting research, patient advocacy, and helping those who live with the challenges of chronic pain. Come out and support this incredible cause, and let’s make a difference together! Please register for 16th Annual Miles for Migraine - https://lnkd.in/gaGwKP95 #Scilex #MilesforMigraine #ChronicPainAwareness #GoldenGatePark #Healthcare #MigraineAwareness #TeamScilex
Scilex Holding Company
Pharmaceutical Manufacturing
Palo Alto, California 3,100 followers
Striving to Revolutionize the World of Non-Opioid Pain Management
About us
SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief. Click here for ZTLido’s Important Safety Information and US Prescribing Information. We have acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®. GLOPERBA® is indicated for the prophylaxis of gout flares in adults. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults. We launched ELYXYB® in the U.S. in April 2023 and are planning to commercialize GLOPERBA® in 2024. SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most. Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido®, has recently completed a Phase 2 trial in acute lower back pain ; Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.
- Website
-
http://www.scilexholding.com
External link for Scilex Holding Company
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2019
- Specialties
- Pain and non-opioid
Locations
-
Primary
960 San Antonio Rd
100
Palo Alto, California 94303, US
-
960 San Antonio Road
Suite 100
Palo Alto, California 94303, US
Employees at Scilex Holding Company
Updates
-
Do you suffer from morning migraine or rapid onset migraine? These can strike suddenly without warning, making it hard to stay on track. In those moments, what you need most is rapid pain freedom, allowing you to quickly regain control and continue with your daily activities. When you need an option that works fast, go to ELYXYB.
-
Scilex is thrilled to be at the Congress of Clinical Rheumatology West! 🎉 Our team is engaging with healthcare professionals and presenting Scilex’s latest innovations in pain management. It’s inspiring to be part of such a vibrant community dedicated to improving care for patients living with chronic pain. If you’re attending, make sure to visit us and learn more about our solutions that are transforming the future of pain management. #CCRWest #Rheumatology #ChronicPain #PainManagement #Scilex #HealthcareInnovation
-
🎉 Today, we celebrated Hispanic Heritage Month with a fantastic employee engagement festivity that honored the rich and diverse cultures within our community! It was a great opportunity to come together, learn, and celebrate the contributions of Hispanic culture. We were also thrilled to welcome our new Territory Business Managers, who were on-site for their training. It was wonderful to meet them in person and share this vibrant celebration with the team. Thank you to everyone who helped make this event a success! #HispanicHeritageMonth #DiversityAndInclusion #EmployeeEngagement #TeamScilex #CultureAndCommunity
-
5
-
Scilex Holding Company reposted this
🟣 September is Pain Awareness Month! 🟣 At Scilex, we understand the impact that chronic pain can have on daily life. That’s why we’re committed to providing effective, non-opioid solutions to help you manage pain and reclaim your day. #painmanagement#awarenessmonth
-
🌟 Strategizing for Success! 🌟 This week, the Scilex POA Team aligned on key strategies to drive growth and innovation! These POA meetings take place all over the country annually with our National Commercial Team alongside with Medical Affairs and Management. Thank you to all who brought their expertise and energy to the table. Exciting times ahead! 💡 #Leadership #Teamwork #BusinessGrowth #Innovation #ScilexSuccess
-
Press Release: Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan https://lnkd.in/gM3vhhzz #pressrelease#ScilexPR
-
🎉 Celebrating Hispanic & Latin American Heritage Month 🎉 At Scilex, we honor the rich cultures, contributions, and diversity of Hispanic and Latin American communities. We are proud to foster an inclusive workplace that celebrates everyone’s unique heritage. #HispanicHeritageMonth #LatinAmericanHeritageMonth #Diversity #Inclusion #Scilex